Under the catalysis of dioxygenase L-arginine is converted to L-citrulline and nitric oxide,the latter exhibits endothelium derived relaxing factor(EDRF)-like actions.N^G-nitro-L-arginine has an inhibitory effect on t...Under the catalysis of dioxygenase L-arginine is converted to L-citrulline and nitric oxide,the latter exhibits endothelium derived relaxing factor(EDRF)-like actions.N^G-nitro-L-arginine has an inhibitory effect on the biosynthesis of EDRF in vitro and in vivo,hence it is an EDRF antagonist.The results of the present work indicate that both N^G-NO_2-L-Arg-OH and HCl·N^G-NO_2-L- Arg-OCH_3 have vasodilating effect in vitro,but produced dose-depending increase in mean arterial blood pressure(MAP)in vivo.In vitro HCl·N_G-NO_2-L-Arg-N_G-NO_2-L-Arg-OCH_3 relaxed rat aortic strip pretreated with noradrenaline(NE).In vivo,however,it produced biphasic effect,i.e,decreased MAP at lower dose and increases MAP at higher dose, N_G-Tos-L-Arg-N_G-Tos-L-Arg-OH produced dose-depending vasodilating and hypotensive actions.展开更多
Based on the EDRF(endothelium derived relaxing factor)-like effects for polyarginine Arg-Arg-oH was selected as the lead compound and its derivatives Arg-Arg- OCH_3.Arg Arg-Arg-OH,HO-ArgCOCH_2CH_2COArg-OH,HO-ArgCOCH_2...Based on the EDRF(endothelium derived relaxing factor)-like effects for polyarginine Arg-Arg-oH was selected as the lead compound and its derivatives Arg-Arg- OCH_3.Arg Arg-Arg-OH,HO-ArgCOCH_2CH_2COArg-OH,HO-ArgCOCH_2COArg-OH,were synthesized.These substances showed on bioassay various degrees of vasorelaxant activities. With protection for the C-terminal of Arg-Arg-OH with a methyl ester.the vasorelaxing ac- tivitv was decreased.In contrast.when the N-terminal of Arg-OH was protected with mal- onic acid or butane diacid.the biological activites were lower than those of Arg-Arg-OH due to the lowered metabolic rate.With protection of N-terminal of Arg-Arg-OH with L-Arg residue.Arg-Arg-Arg-OH was obtained,which showed a vasorelaxing activity better than that of Arg-Arg-OH.The bioactivities observed on the Wister's rats for the former com- pound become the experimental basis for prodrug design of EDRF.展开更多
基金This project was supported by the Natural Sciences Foundation of Beijing.
文摘Under the catalysis of dioxygenase L-arginine is converted to L-citrulline and nitric oxide,the latter exhibits endothelium derived relaxing factor(EDRF)-like actions.N^G-nitro-L-arginine has an inhibitory effect on the biosynthesis of EDRF in vitro and in vivo,hence it is an EDRF antagonist.The results of the present work indicate that both N^G-NO_2-L-Arg-OH and HCl·N^G-NO_2-L- Arg-OCH_3 have vasodilating effect in vitro,but produced dose-depending increase in mean arterial blood pressure(MAP)in vivo.In vitro HCl·N_G-NO_2-L-Arg-N_G-NO_2-L-Arg-OCH_3 relaxed rat aortic strip pretreated with noradrenaline(NE).In vivo,however,it produced biphasic effect,i.e,decreased MAP at lower dose and increases MAP at higher dose, N_G-Tos-L-Arg-N_G-Tos-L-Arg-OH produced dose-depending vasodilating and hypotensive actions.
基金This project was supported by the National Natural Science Foundation of China
文摘Based on the EDRF(endothelium derived relaxing factor)-like effects for polyarginine Arg-Arg-oH was selected as the lead compound and its derivatives Arg-Arg- OCH_3.Arg Arg-Arg-OH,HO-ArgCOCH_2CH_2COArg-OH,HO-ArgCOCH_2COArg-OH,were synthesized.These substances showed on bioassay various degrees of vasorelaxant activities. With protection for the C-terminal of Arg-Arg-OH with a methyl ester.the vasorelaxing ac- tivitv was decreased.In contrast.when the N-terminal of Arg-OH was protected with mal- onic acid or butane diacid.the biological activites were lower than those of Arg-Arg-OH due to the lowered metabolic rate.With protection of N-terminal of Arg-Arg-OH with L-Arg residue.Arg-Arg-Arg-OH was obtained,which showed a vasorelaxing activity better than that of Arg-Arg-OH.The bioactivities observed on the Wister's rats for the former com- pound become the experimental basis for prodrug design of EDRF.
